The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Novel Adipose Tissue–Mediated Resistance to Diet-Induced Visceral Obesity in 11β-Hydroxysteroid Dehydrogenase Type 1–Deficient Mice
Open accessAbstract
The metabolic syndrome (visceral obesity, insulin resistance, type 2 diabetes, and dyslipidemia) resembles Cushing’s Syndrome, but without elevated circulating glucocorticoid levels. An emerging concept suggests that the aberrantly elevated levels of the intracellular glucocorticoid reamplifying enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) found in adipose tissue of obese humans and rodents underlies the phenotypic similarities between idiopathic and “Cushingoid” obesity. Transgenic overexpression of 11β-HSD-1 in adipose tissue reproduces a metabolic syndrome in mice, whereas 11β-HSD-1 deficiency or inhibition has beneficial metabolic effects, at least on liver metabolism. Here we report novel protective effects of 11β-HSD-1 deficiency on adipose function, distribution, and gene expression in vivo in 11β-HSD-1 nullizygous (11β-HSD-1−/−) mice. 11β-HSD-1−/− mice expressed lower resistin and tumor necrosis factor-α, but higher peroxisome proliferator–activated receptor-γ, adiponectin, and uncoupling protein-2 mRNA levels in adipose, indicating insulin sensitization. Isolated 11β-HSD-1−/− adipocytes exhibited higher basal and insulin-stimulated glucose uptake. 11β-HSD-1−/− mice also exhibited reduced visceral fat accumulation upon high-fat feeding. High-fat–fed 11β-HSD-1−/− mice rederived onto the C57BL/6J strain resisted diabetes and weight gain despite consuming more calories. These data provide the first in vivo evidence that adipose 11β-HSD-1 deficiency beneficially alters adipose tissue distribution and function, complementing the reported effects of hepatic 11β-HSD-1 deficiency or inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These include increased production of inflammatory cytokines, 35,36 plasminogen activator inhibitor-1, 37 and other bioactive products 38 -40 ; at the same time the potentially protective adipokine, adiponectin, is reduced.41,42”
From Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (2005) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Leptin and the regulation of body weight in mammals
Friedman, J. M., & Halaas, J. L. (1998) · Nature · doi:10.1038/27376 · Cited by 5,405
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4318 · Cited by 2,164
Relation of Body Fat Distribution to Metabolic Complications of Obesity*
KISSEBAH, A. H., VYDELINGUM, N., MURRAY, R., EVANS, D. J., KALKHOFF, R. K., & ADAMS, P. W. (1982) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-54-2-254 · Cited by 1,909
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766
Self-citationTowards a molecular understanding of adaptive thermogenesis
Lowell, B. B., & Spiegelman, B. M. (2000) · Nature · doi:10.1038/35007527 · Cited by 1,630
Adipogenesis and Obesity: Rounding Out the Big Picture
Spiegelman, B. M., & Flier, J. S. (1996) · Cell · doi:10.1016/s0092-8674(00)81359-8 · Cited by 1,262
Self-citation
Cited by
Sorted by citations
Items 201–300 of 546
Muñoz, R., Carvajal, C. A., Escalona, A., Boza, C., Pérez, G., Ibañez, L. A., & Fardella, C. (2008) · Obesity Surgery · doi:10.1007/s11695-008-9616-6 · Cited by 35
11β-HSD1 Modulates the Set Point of Brown Adipose Tissue Response to Glucocorticoids in Male Mice
Doig, C. L., Fletcher, R. S., Morgan, S., McCabe, E. L., Larner, D. P., Tomlinson, J., Stewart, P. M., Philp, A., & Lavery, G. G. (2017) · Endocrinology · doi:10.1210/en.2016-1722 · Cited by 35
Association of estrogen with glucocorticoid levels in visceral fat in postmenopausal women
Yamatani, H., Takahashi, K., Yoshida, T., Takata, K., & Kurachi, H. (2013) · Menopause · doi:10.1097/gme.0b013e318271a640 · Cited by 34
11β-Hydroxysteroid dehydrogenase type 1: potential therapeutic target for metabolic syndrome
Joharapurkar, A. A., Dhanesha, N., Shah, G. B., Kharul, R. K., & Jain, M. R. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70903-9 · Cited by 34
“Similarly, disruption of 11b-HSD1 in an obesity/diabetes prone strain results in a more favorable adipose tissue distribution as well as protection from diabetes and weight gain upon high-fat feeding, with less fat pad weight despite no change in feed intake [37].”
Mitić, T., Shave, S., Semjonous, N. M., McNae, I. W., Cobice, D., Lavery, G. G., Webster, S. P., Hadoke, P. W. F., Walker, B. R., & Andrew, R. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.002 · Cited by 36
Self-citationBruley, C., Lyons, V., Worsley, A. G. F., Wilde, M. D., Darlington, G., Morton, N. M., Seckl, J. R., & Chapman, K. E. (2006) · Endocrinology · doi:10.1210/en.2005-1621 · Cited by 34
Self-citationHale, C., Véniant, M. M., Wang, Z., Chen, M., McCormick, J., Cupples, R. L., Hickman, D., Min, X., Sudom, A. M., Xu, H., et al. (2007) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2007.00603.x · Cited by 34
Shapiro, A. M., Matheny, M. E., Zhang, Y., Tümer, N., Cheng, K., Rogrigues, E., Zolotukhin, S., & Scarpace, P. J. (2007) · Diabetes · doi:10.2337/db07-0863 · Cited by 36
“This evidence suggests an additional potential mechanism underlying the weight loss synergy between WR and leptin and resonates with studies in which selective decreases in 11β-HSD1 alleviates obesityrelated metabolic complications (34; 35).”
BackgroundHormonal Regulation of Adipogenesis
Lee, M. (2017) · Comprehensive physiology · doi:10.1002/cphy.c160047 · Cited by 47
Vogel, H., Scherneck, S., Kanzleiter, T., Benz, V., Kluge, R., Stadion, M., Kryvych, S., Blüher, M., Klöting, N., Joost, H., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds213 · Cited by 33
Sakamuri, S. S. V. P., Sukapaka, M., Prathipati, V. K., Nemani, H., Putcha, U. K., Pothana, S., Koppala, S. R., Ponday, L. R. K., Acharya, V., Giridharan, N. V., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050216 · Cited by 33
McInnes, K. J., Andersson, T., Šimonytė, K., Söderström, I., Mattsson, C., Seckl, J. R., & Olsson, T. (2012) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318258aad7 · Cited by 33
Self-citationOda, S., Ashida, K., Uchiyama, M., Sakamoto, S., Hasuzawa, N., Nagayama, A., Wang, L., Nagata, H., Sakamoto, R., Kishimoto, J., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab450 · Cited by 32
Mitić, T., Andrew, R., Walker, B. R., & Hadoke, P. W. F. (2012) · Biochimie · doi:10.1016/j.biochi.2012.08.007 · Cited by 32
Self-citationXiang, J. S., Wan, Z., Li, H., Ipek, M., Binnun, E., Nunez, J., Chen, L.-R., McKew, J. C., Mansour, T. S., Xu, X., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8004948 · Cited by 32
Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 in Obesity
Wake, D. J., & Walker, B. R. (2006) · Endocrine · doi:10.1385/endo:29:1:101 · Cited by 32
Self-citationGarcia, R. A., Search, D. J., Lupisella, J. A., Ostrowski, J., Guan, B., Chen, J., Yang, W.-P., Truong, A. B., He, A., Zhang, R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053192 · Cited by 31
Turban, S., Liu, X., Ramage, L. E., Webster, S. P., Walker, B. R., Dunbar, D. R., Mullins, J. J., Seckl, J. R., & Morton, N. M. (2012) · Diabetes · doi:10.2337/db11-1054 · Cited by 31
Self-citationVerma, M., Kipari, T. M. J., Zhang, Z., Man, T. Y., Forster, T., Homer, N. Z. M., Seckl, J. R., Holmes, M. C., & Chapman, K. E. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.11.015 · Cited by 31
“In the periphery, 11b-HSD1-deficiency alters intermediary metabolism and cellular glucose uptake (Morton et al., 2001, 2004; Wamil et al., 2011).”
BackgroundSelf-citationOxazolones as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1
Sutin, L., Andersson, S., Bergquist, L., Castro, V. M., Danielsson, E., James, S. R., Henriksson, M., Johansson, L., Kaiser, C., Flyrén, K., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.06.054 · Cited by 31
Mineralocorticoid Action in the Aldosterone-Sensitive Distal Nephron
Verrey, F., Hümmler, E., Schild, L., & Rossier, B. C. (2008) · Elsevier eBooks · doi:10.1016/b978-012088488-9.50035-8 · Cited by 30
11β-Hydroxysteroid dehydrogenase type 1—A role in inflammation?
Chapman, K. E., Gilmour, J. S., Coutinho, A. E., Savill, J., & Seckl, J. R. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.11.036 · Cited by 31
Self-citationHamilton, B. S., Himmelsbach, F., Nar, H., Schuler‐Metz, A., Krosky, P. M., Guo, J., Guo, R., Meng, S., Zhao, Y., Lala, D. S., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.10.053 · Cited by 30
Liu, Y. U., Park, F., Pietrusz, J. L., Jia, G., Singh, R. J., Netzel, B. C., & Liang, M. (2007) · Physiological Genomics · doi:10.1152/physiolgenomics.00067.2007 · Cited by 30
Even, S., Dulak-Lis, M. G., Touyz, R. M., & Cat, A. N. D. (2014) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2014-0013 · Cited by 30
Takaya, J., Iharada, A., Okihana, H., & Kaneko, K. (2013) · Nutrition Research · doi:10.1016/j.nutres.2013.07.015 · Cited by 33
“[26] Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, et al.”
BackgroundYe, Y., Zhou, Z., Zou, H., Shen, Y., Xu, T., Tang, J. Y., Yin, H.-Z., Chen, M., Leng, Y., & Shen, J. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.05.082 · Cited by 30
Pharmacological Targeting of Adipocytes/Fat Metabolism for Treatment of Obesity and Diabetes
Pilch, P. F., & Bergenhem, N. C. H. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.026104 · Cited by 31
“Mice lacking a functional 11 -HSD gene have been shown to be resistant to developing obesity and diabetes when put on a high-fat diet, even when consuming more calories than wildtype mice (Morton et al., 2004).”
BackgroundLivingstone, D. E. W., Grassick, S. L., Currie, G. L., Walker, B. R., & Andrew, R. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0003 · Cited by 30
“…et al. 2000, Liu et al. 2003) and human obesity (Bujalska et al. 1997, Fraser et al. 1999, Rask et al. 2001) and the effects of 11b-HSD1 deficiency (Morton et al. 2004) or inhibition (Alberts et al. 2002, Hermanowski-Vosatka et al. 2005) to protect against obesity- associated metabolic…”
BackgroundResultInfluentialSelf-citationVeyrat‐Durebex, C., Deblon, N., Caillon, A., Andrew, R., Altirriba, J., Odermatt, A., & Rohner‐Jeanrenaud, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034002 · Cited by 29
“Glucose intolerance and muscle insulin resistance are associated with increased adipose tissue 11b-HSD1 activity in obese humans [17], as well as adipose tissue insulin resistance in mice [18].”
BackgroundTargeting thermogenesis and related pathways in anti-obesity drug discovery
Clapham, J. C., & Arch, J. R. S. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.04.004 · Cited by 31
“It is clear that 11βHSD-1 influences energy expenditure in mice because mice that lack this enzyme have raised energy expenditure and are protected from diet-induced obesity (Morton et al., 2004).”
BackgroundMetabolic syndrome is a low-grade systemic inflammatory condition
Das, U. N. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.19 · Cited by 29
Walker, G. E., Marzullo, P., Prodam, F., Bona, G., & Blasio, A. M. D. (2013) · Endocrine · doi:10.1007/s12020-013-0040-x · Cited by 29
“Consistent with this, 11b-HSD1 knockout (11b-HSD1) mice chronically fed a high-fat (HF) diet resist MetS in part by preferentially accumulating peripheral rather than visceral fat [21], with distinct depotspecific mechanisms driving this healthier fat pattern and mRNA Expression”
BackgroundFotsch, C. H., Bartberger, M. D., Bercot, E. A., Chen, M., Cupples, R. L., Emery, M., Fretland, J., Guram, A. S., Hale, C., Han, N., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801073z · Cited by 29
A novel 11β-HSD1 inhibitor improves diabesity and osteoblast differentiation
Park, J. S., Bae, S. J., Choi, S., Son, Y. H., Park, S. B., Rhee, S. D., Kim, H. Y., Jung, W. H., Kang, S. K., Ahn, J. H., et al. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0177 · Cited by 29
“…Printed in Great Britain as central obesity, glucose intolerance, and insulin resistance (Masuzaki et al. 2001), but those tissues fromHsd11b1 knock-out mice showed a reduction in high-fat dietinduced obesity with improved insulin sensitivity and lipid profiles (Morton et al. 2004).”
BackgroundTime of the day for 11β‐HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice
Véniant, M. M., Hale, C., Komorowski, R., Chen, M. M., Jean, D. J. S., Fotsch, C. H., & Wang, M. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00911.x · Cited by 29
Equisetin is an anti-obesity candidate through targeting 11β-HSD1
Xu, Z., Liu, D., Liu, D., Ren, X., Liu, H., Qi, G., Zhou, Y. T., Wu, C., Zhu, K., Zou, Z., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.006 · Cited by 28
Arai, N., Masuzaki, H., Tanaka, T., Ishii, T., Yasue, S., Kobayashi, N., Tomita, T., Noguchi, M., Kusakabe, T., Fujikura, J., et al. (2007) · Endocrinology · doi:10.1210/en.2007-0349 · Cited by 28
Self-citationPaternain, L., García‐Díaz, D. F., Milagro, F. I., González‐Muniesa, P., Martínez, J. A., & Campión, J. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.01.017 · Cited by 28
“Consistent with a relative deficiency of glucocorticoid signaling in adipose tissue [80,86], transcript levels of AGT was markedly lower in the adipose tissue of animals fed a high-fat diet.”
El tejido graso como modulador endocrino: Cambios hormonales asociados a la obesidad
René Baudrand, B., Eugenio Arteaga, U., & Manuel Moreno, G. (2010) · Revista médica de Chile · doi:10.4067/s0034-98872010001100015 · Cited by 28
Šimonytė, K., Olsson, T., Näslund, I., Angelhed, J., Lönn, L., Mattsson, C., & Rask, E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2472 · Cited by 28
“11 -HSD1 knockout mice exhibited reduced visceral fat accumulation, insulin resistance, reduced leptin, and increased AT adiponectin mRNA expression levels when fed a high-fat diet (8, 9).”
Tsai, S., Hung, H., Shih, M. M., Chang, F., Chung, B., Wang, C., Lin, Y., & Kuo, Y. (2021) · The FASEB Journal · doi:10.1096/fj.202101570r · Cited by 28
Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient
Rochester, C. D. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i3.305 · Cited by 29
Harno, E., Cottrell, E. C., Yu, A., deSchoolmeester, J., Gutierrez, P. M., Denn, M., Swales, J. G., Goldberg, F. W., Bohlooly‐Y, M., Andersén, H., et al. (2013) · Endocrinology · doi:10.1210/en.2013-1613 · Cited by 28
Espíndola-Antunes, D., & Kater, C. E. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000800027 · Cited by 28
“In contrast, 11βHSD1knockout mice are protected from obesity and its metabolic complications (9).”
BackgroundDammann, C., Stapelfeld, C., & Maser, E. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.02.018 · Cited by 28
Salehzadeh, F., Al‐Khalili, L., Kulkarni, S. S., Wang, M., Lönnqvist, F., & Krook, A. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.944 · Cited by 27
“HSD1 deficient mice are insulin sensitive and are resistant to dietary-induced insulin resistance [14,15].”
BackgroundObesity drugs and their targets: correlation of mouse knockout phenotypes with drug effects in vivo
Powell, D. R. (2006) · Obesity Reviews · doi:10.1111/j.1467-789x.2006.00220.x · Cited by 28
“11-beta hydroxysteroid dehydrogenase (193)”
Kovačević, S., Brkljačić, J. M., Matić, G. M., & Elaković, I. (2014) · European Journal of Nutrition · doi:10.1007/s00394-013-0644-1 · Cited by 30
“Transgenic mice overexpressing 11bHSD1 in the adipose tissue develop phenotype characteristics of metabolic syndrome, including central adiposity [16], while 11bHSD1 knockout mice are resilient to obesity and accompanying complications [19].”
BackgroundAuvinen, A. P., Romijn, J. A., Biermasz, N. R., Havekes, L. M., Smit, J. W. A., Rensen, P. C. N., & Pereira, A. M. (2011) · Hormone and Metabolic Research · doi:10.1055/s-0031-1291305 · Cited by 29
Will treating diabetes with 11β-HSD1 inhibitors affect the HPA axis?
Harno, E., & White, A. E. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.06.004 · Cited by 27
Edgerton, D. S., Basu, R., Ramnanan, C. J., Farmer, T. D., Neal, D. W., Scott, M. F., Jacobson, P. B., Rizza, R. A., & Cherrington, A. D. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00740.2009 · Cited by 29
Mineralocorticoid Excess or Glucocorticoid Insufficiency
Mullins, L. J., Kenyon, C. J., Bailey, M. A., Conway, B. R., Díaz, M. E., & Mullins, J. J. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05262 · Cited by 27
Self-citationLutz, S. Z., Peter, A., Machicao, F. E., Lamprinou, A., Machann, J., Schick, F., Königsrainer, I., Königsrainer, A., Fritsche, A., Staiger, H., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2498 · Cited by 27
Lee, J. H., Gao, Z., & Ye, J. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00029.2013 · Cited by 27
Burén, J., Bergström, S., Loh, E., Söderström, I., Olsson, T., & Mattsson, C. (2007) · Endocrinology · doi:10.1210/en.2006-0897 · Cited by 26
Cobice, D., Livingstone, D. E. W., McBride, A., Mackay, C. L., Walker, B. R., Webster, S. P., & Andrew, R. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.12.013 · Cited by 26
Self-citationXenobiotic Metabolising Enzymes: Impact on Pathologic Conditions, Drug Interactions and Drug Design
Rekka, E. A., Kourounakis, P. N., & Pantelidou, M. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190129122727 · Cited by 26
Synthesis and biological evaluation of heterocycle containing adamantane 11β-HSD1 inhibitors
Yeh, V. S. C., Patel, J. R., Yong, H., Kurukulasuriya, R., Fung, S., Monzon, K., Chiou, W. J. H., Wang, J., Stolarik, D. F., Imade, H. M., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.07.055 · Cited by 26
Glucocorticoids decrease serum adiponectin level and WAT adiponectin mRNA expression in rats
Shi, J.-H., Du, W.-H., Liu, X., Fan, Y., Hu, X., Zhou, H., Xu, H., Zhang, X., Xiang, P., & Chen, F. (2010) · Steroids · doi:10.1016/j.steroids.2010.05.001 · Cited by 25
Sun, D., Wang, Z., Cardozo, M. G., Choi, R. J., DeGraffenreid, M. R., Di, Y., He, X., Jaén, J. C., Labelle, M., Liu, J., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.114 · Cited by 25
The Role of Cortisol in the Pathogenesis of the Metabolic Syndrome
Jeong, I. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.3.207 · Cited by 25
“Furthermore, 11β-HSD1 knockout mice have a reduced risk of obesity and MetS [28].”
BackgroundNikolaou, N., Gathercole, L., Kirkwood, L., Dunford, J. E., Hughes, B. A., Gilligan, L. C., Oppermann, U. C. T., Penning, T. M., Arlt, W., Hodson, L., et al. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.02.002 · Cited by 24
Spirocyclic ureas: Orally bioavailable 11β-HSD1 inhibitors identified by computer-aided drug design
Tice, C. M., Zhao, W. L., Xu, Z., Cacatian, S. T., Simpson, R. D., Ye, Y.-J., Singh, S. B., McKeever, B. M., Lindblom, P., Guo, J., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.12.082 · Cited by 25
Splanchnic Cortisol Production in Dogs Occurs Primarily in the Liver
Basu, R., Edgerton, D. S., Singh, R., Cherrington, A. D., & Rizza, R. A. (2006) · Diabetes · doi:10.2337/db06-0601 · Cited by 25
“Visceral CP NVisceral CB Visceral CU (8)”
11β-HSD1 reduces metabolic efficacy and adiponectin synthesis in hypertrophic adipocytes
Koh, E. H., Kim, A., Kim, H., Kim, J. H., Park, H., Ko, M. S., Kim, M., Kim, H.-J., Kim, B. J., Yoo, H. J., et al. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0117 · Cited by 23
Targeting Components of the Stress System as Potential Therapies for the Metabolic Syndrome
Yumuk, V. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1367.019 · Cited by 24
Malavasi, E. L. V., Kelly, V., Nath, N., Gambineri, A., Dakin, R. S., Pagotto, U., Pasquali, R., Walker, B. R., & Chapman, K. E. (2009) · Endocrinology · doi:10.1210/en.2009-0663 · Cited by 24
“Conversely, 11βHSD1 inhibition increases hepatic insulin sensitivity in humans (8) and its deficiency or inhibition ameliorates the metabolic consequences of obesity, increasing insulin sensitivity and reducing blood glucose levels in obese or diabetic mice (9-13).”
Self-citationInhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 in Antidiabetic Therapy
Wang, M. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_6 · Cited by 24
Stewart, P. M. (2005) · Clinical Medicine · doi:10.7861/clinmedicine.5-2-142 · Cited by 23
Pathophysiological Link between Insulin Resistance and Adrenal Incidentalomas
Higgs, J. A., Quinn, A. P., Seely, K. D., Richards, Z., Mortensen, S. P., Crandall, C. S., & Brooks, A. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084340 · Cited by 26
Man, T. Y., Michailidou, Z., Gökçel, A., Ramage, L. E., Chapman, K. E., Kenyon, C. J., Seckl, J. R., & Morton, N. M. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00531.2010 · Cited by 23
“11β-HSD1-deficient mice resist high-fat diet-induced obesity (DIO) due to beneficial changes in fat distribution and insulin sensitivity of adipose tissue and liver (28, 29).”
BackgroundInfluentialSelf-citationKoška, J., de Courten, B. V., Wake, D. J., Nair, S., Walker, B. R., Bunt, J. C., Permana, P. A., Lindsay, R. S., & Tataranni, P. A. (2006) · Obesity · doi:10.1038/oby.2006.175 · Cited by 23
Self-citationRyu, J. H., Lee, J. A., Kim, S., Shin, Y. A., Yang, J., Han, H. Y., Son, H. J., Kim, Y. H., Sa, J. H., Kim, J.-S., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01122 · Cited by 22
Miguet, L., Zhang, Z., Barbier, M., & Grigorov, M. (2006) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-006-9037-3 · Cited by 22
Kim, S. H., Bok, J. H., Lee, J. H., Kim, I. H., Kwon, S. W., Lee, G. B., Kang, S. K., Park, J. S., Jung, W. H., Kim, H. Y., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200226x · Cited by 22
Intravascular Glucocorticoid Metabolism during Inflammation and Injury in Mice
Dover, A. R., Hadoke, P. W. F., Macdonald, L. J., Miller, E., Newby, D. E., & Walker, B. R. (2006) · Endocrinology · doi:10.1210/en.2006-0996 · Cited by 22
Self-citationMichailidou, Z., Coll, A. P., Kenyon, C. J., Morton, N. M., O’Rahilly, S., Seckl, J. R., & Chapman, K. E. (2007) · Journal of Endocrinology · doi:10.1677/joe-07-0090 · Cited by 21
Self-citationEsteves, C. L., Kelly, V., Bégay, V., Man, T. Y., Morton, N. M., Leutz, A., Seckl, J. R., & Chapman, K. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037953 · Cited by 21
“. In contrast, 11β-HSD1-deficiency or inhibition causes insulin-sensitization (including in humans), lowers fasting plasma glucose and lipid levels, reduces visceral adipose tissue mass and attenuates atherosclerosis”
BackgroundSelf-citationHypoadiponectinemia as a Marker of Adipocyte Dysfunction—Part I: The Biology of Adiponectin
Stern, N., Osher, E., & Greenman, Y. (2007) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4564.2007.06597.x · Cited by 21
Kim, E., Kim, E. J., Seo, S.-W., Hur, C., McGregor, R. A., & Choi, M. (2013) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2011.619283 · Cited by 22
“Insulin secretion Lipid metabolic process Peroxisome proliferator-activated receptor γ (Pparg) ↑ Cell fate commitment (Soukas et al., 2000; Morton et al., 2004; Hosogai et al., 2007; Kim et al., 2008; Kim and Kim, 2009; Kim and Park, 2010) Fat cell differentiation Fatty acid oxidation Inflammatory response Long-chain…”
BackgroundIdentification of microRNAs as a potential novel regulatory mechanism in HSD11B1 expression
Han, Y., Staab-Weijnitz, C. A., Xiong, G., & Maser, E. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.09.005 · Cited by 21
Discovery of orally active butyrolactam 11β-HSD1 inhibitors
Yeh, V. S. C., Kurukulasuriya, R., Fung, S., Monzon, K., Chiou, W. J. H., Wang, J., Stolarik, D. F., Imade, H. M., Shapiro, R. D., Knourek-Segel, V. E., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.034 · Cited by 21
Inhibition of 11β-hydroxysteroid dehydrogenase type 1 ameliorates obesity-related insulin resistance
Shao, S., Zhang, X., & Zhang, M. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.06.015 · Cited by 21
Abulizi, A., Camporez, J. P., Zhang, D., Samuel, V. T., Shulman, G. I., & Vatner, D. F. (2018) · Metabolism · doi:10.1016/j.metabol.2018.12.003 · Cited by 21
Kim, S. H., Kwon, S. W., Chu, S. Y., Lee, J. H., Narsaiah, B., Kim, C. H., Kang, S. K., Kang, N. S., Rhee, S. D., Bae, M. A., et al. (2011) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.59.46 · Cited by 21
Kuhn, E., Bourgeois, C., Keo, V., Viengchareun, S., Muscat, A., Méduri, G., Menuet, D. L., Fève, B., & Lombès, M. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00323.2013 · Cited by 23
Sakamuri, S. S. V. P., Anamthathmakula, P., Kumar, C. P., Reddy, S. J., Giridharan, N. V., & Vajreswari, A. (2010) · Lipids in Health and Disease · doi:10.1186/1476-511x-9-132 · Cited by 20
“Adipose-specific overexpression of 11b -HSD1 in mice resulted in the development of majority of metabolic syndrome features including visceral obesity and insulin resistance [7], where as 11b-HSD1 knock-out in mice resulted in the development of resistance to diet-induced obesity [ 8 ].”
BackgroundLarner, D. P., Morgan, S., Gathercole, L., Doig, C. L., Guest, P., Weston, C. J., Hazeldine, J., Tomlinson, J., Stewart, P. M., & Lavery, G. G. (2016) · Endocrinology · doi:10.1210/en.2016-1357 · Cited by 21
Sun, D., Wang, Z., Caille, S., DeGraffenreid, M. R., de Turiso, F. G.-L., Hungate, R. W., Jaén, J. C., Jiang, B., Julian, L. D., Kelly, R. C., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.10.129 · Cited by 20
Detection of thermogenesis in rodents in response to anti-obesity drugs and genetic modification
Arch, J. R. S., & Trayhurn, P. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00064 · Cited by 20
“Similarly, 11β-hydroxysteroid dehydrogenase type 1 knockout mice fed on a high fat diet were less obese than wild-type mice, despite having a higher caloric intake (Morton et al., 2004).”
BackgroundAtalar, F., Görmez, S., Çaynak, B., Akan, G., Tanrıverdi, G., Gazioglu, S. B., Günay, D., Duran, C., Akpınar, B., Özbek, U., et al. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-115 · Cited by 18
A gene variant of 11β-hydroxysteroid dehydrogenase type 1 is associated with obesity in children
Olza, J., Gil‐Campos, M., Leis, R., Rupérez, A. I., Tojo, R., Cañete, R., Gil, Á., & Aguilera, C. M. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.4 · Cited by 19
Targeting osteoblastic 11β-HSD1 to combat high-fat diet-induced bone loss and obesity
Zhong, C., Li, N., Wang, S., Li, D., Yang, Z., Du, L., Huang, G., Li, H., Yeung, W. S., He, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52965-4 · Cited by 23
Oh, H., Jeong, K., Han, H. Y., Son, H. J., Kim, S. S., Lee, H. J., Kim, S., Sa, J. H., Jun, H., Ryu, J. H., et al. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.10.042 · Cited by 19
Polymorphisms of POR, SULT2A1 and HSD11B1 in children with premature adrenarche
Utriainen, P., Laakso, S. M., Jääskeläinen, J., & Voutilainen, R. (2012) · Metabolism · doi:10.1016/j.metabol.2012.02.008 · Cited by 18
“[15] Morton NM, Paterson JM, Masuzaki H, et al.”
BackgroundByler, K., & Setzer, W. N. (2018) · Medicines · doi:10.3390/medicines5030096 · Cited by 18
“11β-Hydroxysteroid dehydrogenase type 1 mediates the interconversion of cortisone and cortisol and overexpression of 11βHSD1 can lead to metabolic disease, characterized by visceral obesity, hyperlipidemia, hypertension, glucose intolerance, insulin resistance, and type II diabetes [87,88].”
BackgroundTharappel, A. M., Dandu, A., Harsha, K., Singh, J. K., Shree, N., Kumar, V. S., Lakshmi, M. N., Venkategowda, S., Harish, C., Balamurali, G. V., et al. (2014) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-15-43 · Cited by 18
“The role of 11β-HSD1 in obesity is well established both by pharmacological interventions and also by knockout studies [28,30,32,49,50].”
BackgroundBerthiaume, M., Laplante, M., Festuccia, W. T., Berger, J. P., Thieringer, R., & Deshaies, Y. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.33 · Cited by 18
Kwon, S. W., Kang, S. K., Lee, J. H., Bok, J. H., Kim, C. H., Rhee, S. D., Jung, W. H., Kim, H. Y., Bae, M. A., Song, J. S., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.10.123 · Cited by 18
Metadata
- Authors
- Morton, N. M., Paterson, J. M., Masuzaki, H., Holmes, M. C., Staels, B., Fievet, C., Walker, B. R., Flier, J. S., Mullins, J. J., & Seckl, J. R.
- Affiliations
- Western General Hospital (GB)
- University of Edinburgh (GB)
- Kyoto University (JP)
- Inserm (FR)
- Département d’ Athérosclérose,U.545 INSERM, Institut Pasteur de Lille, Lille, France
- Beth Israel Deaconess Medical Center (US)
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2004-04-01
- Volume
- 53
- Issue
- 4
- Pages
- 931-938
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2154972651
- Cited by
- 512
- References
- 49
- Citations by year
- 2026: 10 · 2025: 7 · 2024: 9 · 2023: 6 · 2022: 9 · 2021: 9 · 2020: 5 · 2019: 10 · 2018: 10 · 2017: 12 · 2016: 21 · 2015: 19 · 2014: 24 · 2013: 35 · 2012: 37
- FWCI
- 32.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- 11β-hydroxysteroid dehydrogenase type 1, visceral obesity, adipose tissue, metabolic syndrome, insulin resistance, resistin, TNF-α, PPARγ, adiponectin, UCP2, insulin-stimulated glucose uptake, high-fat diet, body fat distribution, type 2 diabetes
- MeSH terms
- Uncoupling Protein 2, Adipose Tissue, Animals, Blood Glucose, Body Temperature, Body Weight, Cholesterol, Diet, Gene Expression Regulation, Glucose Tolerance Test, Insulin, Ion Channels, Male, Obesity, Transcription Factors, Triglycerides, Adipocytes, Receptors, Cytoplasmic and Nuclear, Mice, Knockout, Mitochondrial Proteins, Membrane Transport Proteins, 11-beta-Hydroxysteroid Dehydrogenase Type 1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
